Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > November 18, 2022
Daily News
November 18, 2022
- Astellas’s Zolbetuximab Hits Goals in PIII Gastric Cancer Trial
November 18, 2022
- RaQualia Gets US$4 Million from Asahi Kasei for Chronic Pain Drug Milestone
November 18, 2022
- Horizon Completes Enrollment of Japan PIII for Thyroid Eye Disease Drug
November 18, 2022
- Yoshindo Bags Japan Sales Rights for Stelara, Pralia Biosimilars from India’s Biocon
November 18, 2022
- Increasing Number of Lawmakers Are Against Off-Year Price Revision: JPMA Director General
November 18, 2022
- Big 3 Generic Firms Struggle in H1; Nichi-Iko Logs Excess Debt as Profits Tank for Rivals
November 18, 2022
- Govt to Designate 4 β-Lactam Antibiotics as Key Resources by Year-End
November 18, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…